 |
|
Adding steroid drug to MS treatment may reduce disease activity
April 30, 2009SEATTLE - Using a steroid drug for multiple sclerosis (MS) in addition to an MS drug may reduce the amount of disease activity more than using the MS drug alone, according to a study that will be presented as part of the Late-breaking Science Program at the American Academy of Neurology's 61st Annual Meeting in Seattle, April 25 - May 2, 2009.
For the study, people with MS received the steroid drug methylprednisolone in monthly "pulses," or three doses over three days, in addition to regular weekly treatment with the drug interferon beta-1a. The steroid drug has typically been used only to treat acute MS attacks, not as an ongoing treatment.
The study involved 341 people with relapsing-remitting MS. Half of the participants received both drugs; half received only the interferon drug plus a placebo. The participants were seen every three months during the three-year study for evaluation.
The participants had the disease for an average of three years and had not yet received a disease-modifying drug such as interferon.
Those who received both drugs had 38 percent fewer relapses, or times when the disease is active, than those receiving only the interferon drug. They also improved slightly on a test of MS disability, while the scores for the placebo group decreased slightly.
At the beginning of the study and again after three years, the researchers measured the size of lesions in the brain that are a sign of disease activity. For those receiving both drugs, the lesions stayed the same size or shrunk, while the size of the lesions grew for those taking only interferon.
"These results indicate that these two drugs may have a synergy when taken together and provide a more beneficial effect on the disease activity," said study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark. "This is a promising finding, as the benefit from interferon is only moderate and not everyone responds fully to the treatment, so anything we can do to boost those results is positive."
American Academy of Neurology
The participants had the disease for an average of three years and had not yet received a disease-modifying drug such as interferon.
Those who received both drugs had 38 percent fewer relapses, or times when the disease is active, than those receiving only the interferon drug. They also improved slightly on a test of MS disability, while the scores for the placebo group decreased slightly.
At the beginning of the study and again after three years, the researchers measured the size of lesions in the brain that are a sign of disease activity. For those receiving both drugs, the lesions stayed the same size or shrunk, while the size of the lesions grew for those taking only interferon.
"These results indicate that these two drugs may have a synergy when taken together and provide a more beneficial effect on the disease activity," said study author Mads Ravnborg, MD, of the Danish Multiple Sclerosis Research Center at Copenhagen University Hospital in Denmark. "This is a promising finding, as the benefit from interferon is only moderate and not everyone responds fully to the treatment, so anything we can do to boost those results is positive."
American Academy of Neurology
Interferon Current Events and Interferon News RSSExtending treatment after liver transplant may benefit patients with hepatitis C recurrence
Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.
2-pronged protein attack could be source of SARS virulence
Ever since the previously unknown SARS virus emerged from southern China in 2003, University of Texas Medical Branch at Galveston virologists have focused on finding the source of the pathogen's virulence - its ability to cause disease.
Discovery could improve hepatitis C treatment
Walter and Eliza Hall Institute researchers are part of an international team that has discovered a genetic variation that could identify those people infected with hepatitis C who are most likely to benefit from current treatments.
Fish fend off invading germs with an initial response similar to the one found in people
Since the human response to infection is highly complex, research to understand how people fight infection is facilitated by studying how similar processes occur in simpler organisms.
Researchers prolong the plasma half-life of biopharmaceutical proteins
Many biopharmaceuticals comprise small proteins that are quickly eliminated from the body. Scientists at the Technische Universitaet Muenchen (TUM) combine such small proteins with a kind of molecular balloon that swells and thus prolongs the half-life of the proteins in the body.
Fewer injection site reactions in patients using Avonex
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon beta-1a IM) reported significantly fewer injection site reactions (ISRs) compared to patients on Betaferon® (interferon beta-1b), Copaxone® (glatiramer Acetate) or Rebif ® (interferon beta-1a).
New biomarker predicts response to hepatitis C treatment
Researchers have identified the first genetic marker that predicts response to hepatitis C treatments, and a single letter of DNA code appears to make a huge difference.
Current hepatitis C treatments work equally well, UT Southwestern and national researchers report
The three treatment combinations for clearing the most common form of the hepatitis C virus work equally well with similar side effects, UT Southwestern Medical Center researchers and their colleagues in 13 other institutions have found.
Finding key to cancer drug Gleevec's limitations
University of Michigan researchers have developed an animal model that provides strong evidence why imatinib, marketed as Gleevec, helps patients with chronic myeloid leukemia survive longer, but does not keep the disease from returning if treatment ends.
Researchers Identify New Method to Selectively Kill Metastatic Melanoma Cells
An international team of researchers has identified a new method for selectively killing metastatic melanoma cells, which may lead to new areas for drug development in melanoma - a cancer that is highly resistant to current treatment strategies.
More Interferon Current Events and Interferon News Articles
 |
Interferon: The Science and Selling of a Miracle Drug (Studies in the History of Science, Technology and Medicine) by Toine Pieters (Author) This innovative study charts the beginnings, history and fate of Interferon - one of modern medicine's most famous and infamous drugs. Interferon is part of the medical profession's armoury against viral infection, cancer and MS. The story of its development and use is one of survival in the face of remarkable cycles of promise and disappointment as a miracle drug. By telling this story, Toine Pieters' book provides insight into the research, manufacture, and marketing of new bio-molecules that mark modern medical science. Pieters' closely argued book adopts a multi-disciplinary approach in seeking to trace the extraordinary voyage of interferon. Through the lens of interferon's voyage, the book explores the interaction of the broad range of actors driving medical science: ... |
 |
Living In Oblivion : The 80's Greatest Hits, Vol. 4 by Various Artists |
 |
Interferon / TIME Cover: March 31, 1980, Art Poster by TIME Magazine by barewalls The most eagerly awaited event in the editorial cycle at TIME Magazine is always the selection of the cover. The best covers capture the zeitgeist of the week while surviving the judgment of history. As browsing this collection of TIME cover art prints shows, TIME is as good a record as any of who and what mattered over the past 80-plus years. And so when TIME captures a person, an event or a trend within its iconic red borders, the magazine is adding that extra dose of significance that no other publication can quite match. That is one reason why the original artwork for more than 800 TIME covers now resides in the National Portrait Gallery in Washington. Thanks to an amazing roster of artists, photographers and graphic designers, from TIME's earliest charcoal drawings of cover subjects... |
![interferon [Explicit]](http://ecx.images-amazon.com/images/I/61wymKvfItL._SL160_.jpg) |
interferon [Explicit] Medic (Primary Contributor) |
 |
BioBran - BRM4 (MGN3) (250 Mg/60 Capsules) by Daiwa Pharmaceuticals BRM4 is a rice bran & mushroom enzyme product made by a unique, patented natural process that assists in maintaining a strong immune system. BRM4s active ingredient is clinically shown to triple the immune systems Natural Killer Cell activity. MGN 3® is the brand name of a nutritional supplement that contains the active ingredient; MGN-3 Arabinoxylan Compound, which is contained in BRM4. BRM4 (MGN-3) is safe to use over prolonged periods of time, as it does not cause a hyper-response of the immune system, and does not lose effectiveness with prolonged use. It elevates immune activity to match the challenges of todays environment. BRM4 works to increase B- & T-Cell counts (both helper & cytotoxic T-Cells), acts as an anti-inflammatory and anti-oxidant, as well as anti-viral support. BRM4... |
|
Recurrent injection site reactions from interferon beta 1-b.(CASE REPORTS): An article from: Journal of Drugs in Dermatology by Lena Samuel (Author), Eve J. Lowenstein (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on April 1, 2006. The length of the article is 1344 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Recurrent injection site reactions from interferon beta 1-b.(CASE REPORTS) Author: Lena Samuel Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: April 1, 2006 Publisher: Thomson Gale Volume: 5 Issue: 4 Page: 366(2) Distributed by Thomson... | |
 |
The Interferons: Characterization and Application by Anthony Meager (Editor) At long last, the first book to cover all important areas of interferon science in one volume. Top scientists, including many pioneers in the field, highlight the role of interferons as research tools and as therapeutic agents in clinical applications. Edited by an experienced interferonologist, chapters include discussions of interferon genes, Type I, II and III IFNs, as well as their induction, production and purification, receptors actions, measuring IFN activities and anti-IFN antibodies, as well as the evolution of viral defense mechanisms. For immunologists, cancer researchers, medicinal chemists, cell biologists, developmental biologists and the pharmaceutical industry. |
|
|
Interferon / TIME Cover: March 31, 1980, Art Poster by TIME Magazine by barewalls The most eagerly awaited event in the editorial cycle at TIME Magazine is always the selection of the cover. The best covers capture the zeitgeist of the week while surviving the judgment of history. As browsing this collection of TIME cover art prints shows, TIME is as good a record as any of who and what mattered over the past 80-plus years. And so when TIME captures a person, an event or a trend within its iconic red borders, the magazine is adding that extra dose of significance that no other publication can quite match. That is one reason why the original artwork for more than 800 TIME covers now resides in the National Portrait Gallery in Washington. Thanks to an amazing roster of artists, photographers and graphic designers, from TIME's earliest charcoal drawings of cover subjects... |
 |
Interferon (Dave Clark Mix) X-313 (Primary Contributor) |
 |
Immune Stress Support-Build Immunity Against Winter Colds & Flu! by MyNutritionStore.com IMMUNE STRESS SUPPORT is a powerful, all-natural complex designed to support the immune system, increase energy and combat stress. This synergistic blend of Spirulina, Wheat Grass, adaptogens and B-Complex helps the body adapt and normalize. Spirulina and Wheat Grass are often referred to as miracle foods for their abundant health benefits. Spirulina is a high protein super food known for its ability to support the immune system, protect body tissues from oxidative stress and balance gastrointestinal health. Wheat Grass is known to increase oxygen absorption, reduce toxic build-up and support heart and brain function. Ashwaghanda (Indian Ginseng), is added to improve physical energy, exercise capacity, and support heart and immune health. Astragalus, from Traditional Chinese Medicine, has... |
| © 2009 BrightSurf.com |